Peptide-based vaccines for cancer therapy

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3175-3178

  Parmiani, Giorgio ^a   Russo, Vincenzo ^a   Maccalli, Cristina ^b   Parolini, Danilo ^a   Rizzo, Nathalie ^a   Maio, Michele ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Antigens; Cancer; Epitopes; Immune responses; Vaccination

Indexed keywords

ANTINEOPLASTIC AGENT; CIMAVAX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMA 901; IMMUNOGLOBULIN IDIOTYPE; IMMUNOLOGICAL ADJUVANT; IPILIMUMAB; MELANOMA ANTIGEN 3; PEPTIDE VACCINE; SURVIVIN; TECEMOTIDE; TERTOMOTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; EPITOPE; SUBUNIT VACCINE;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; MELANOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; VACCINATION; VACCINES, SUBUNIT;

EID: 84921761156     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29418     Document Type: Article

References (37)

1. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18:769-78; PMID:13502695
2. Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, et al. Immune rejection of mouse tumors expressing mutated self. Cancer Res 2009; 69:3545-53; PMID:19351857; http://dx.doi.org/10.1158/0008-5472.CAN-08-2779
3. Parmiani G, Pilla L, Maccalli C, Russo V. Autologous versus allogeneic cell-based vaccines? Cancer J 2011; 17:331-6; PMID:21952283; http://dx.doi.org/10.1097/PPO.0b013e3182337a76
4. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-5; PMID:8847150; http://dx.doi.org/10.1002/ijc.2910630622
5. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7; PMID:1840703; http://dx.doi.org/10.1126/science.1840703
6. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14:135-46; PMID:24457417; http://dx.doi.org/10.1038/nrc3670
7. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54:187-207; PMID:15309328; http://dx.doi.org/10.1007/s00262-004-0560-6
8. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255:1261-3; PMID:1546328; http://dx.doi.org/10.1126/science.1546328
9. RammenseeHG, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines 2013; 12:1211-7;PMID:24090147; http://dx.doi.org/10.1586/14760584.2013.836911
10. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94:805-18; PMID:12048268; http://dx.doi.org/10.1093/jnci/94.11.805
11. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10.1038/nm1100
12. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Advances in cancer immunotherapy: Active immunotherapy. Nature Rev Clin Oncology 2014; (Forthcoming)
13. Parmiani G, Russo V, Marrari A, Cutolo G, Casati C, Pilla L, Maccalli C, Rivoltini L, Castelli C. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin Cancer Res 2007; 13:5675-9; PMID:17908956; http://dx.doi.org/10.1158/1078-0432.CCR-07-0879
14. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjöblom T, Park B-H, Parsons R, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 2008; 105:16224-9; PMID:18852474; http://dx.doi.org/10.1073/pnas.0808041105
15. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463:191-6; PMID:20016485; http://dx.doi.org/10.1038/nature08658
16. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281-4; PMID: 7652577; http://dx.doi.org/10.1126/science.7652577
17. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014; 343:189-93; PMID:24336570; http://dx.doi. org/10.1126/science.1239947
18. Jalali SA, Parmiani G. Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors. Recent Pat Biotechnol 2011; 5:108-17; PMID:21707528; http://dx.doi.org/10.2174/187220811796365716
19. Parmiani G, Cimminiello C, Maccalli C. Increasing immunogeni city of cancer vaccines to improve their clinical out come. Exp Rev Vaccines 2013; 10.1586/14760584
20. Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Liénard D, Lejeune F, Cerottini JC, Romero P, Speiser DE. Simultaneous CD8C T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun 2003; 3:15-23; PMID:14580186
21. Slingluff CL Jr., Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21:4016-26; PMID:14581425; http://dx.doi.org/10.1200/JCO.2003.10.005
22. Slingluff CL Jr., Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004; 22:4474-85; PMID:15542798; http://dx.doi.org/10.1200/JCO.2004.10.212
23. Slingluff CL Jr., Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008; 26:4973-80; PMID: 18809608; http://dx.doi.org/10.1200/JCO.2008.17.3161
24. Slingluff CL Jr., Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res 2013; 19:4228-38; PMID:23653149; http://dx.doi.org/10.1158/1078-0432.CCR-13-0002
25. Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, et al. Limited induction of tumor crossreactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides Clin Cancer Res 2012; 18:6485-96; PMID:23032742; http://dx.doi. org/10.1158/1078-0432.CCR-12-1516
26. Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DVT, Polite BN, Rosenbaum C, Namakydoust A, Karrison T, Gajewski TF, et al. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSFvaccine in patients with pancreatic adenocarcinoma. J Immunother Cancer 2013; 1:8; PMID:24829746; http://dx.doi.org/10.1186/2051-1426-1-8
27. Welters MJP, Kenter GG, Piersma SJ, Vloon APG, Löwik MJG, Berends-van der Meer DMA, Drijfhout JW, Valentijn ARPM, Wafelman AR, Oostendorp J, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14:178-87; PMID:18172269; http://dx.doi.org/10.1158/1078-0432.CCR-07-1880
28. Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu W-J, Livingstone PD, Lewis WL, Houghton AN, Chapman PB, et al. T cell responses against tyrosinase 368-376 (370D) peptide in HLA[[ampi]z.ast;A201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, GM-CSF and QS21 as immunological adjuvants. Clin Cancer Res 2002; 20:2610-5
29. Kruit WHJ, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob J-J, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 2013; 31:2413-20; PMID:23715572; http://dx.doi. org/10.1200/JCO.2012.43.7111
30. Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA, White D, Doherty E, Dranoff G, Mooney DJ. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res 2014; 74:1670-81; PMID:24480625; http://dx.doi.org/10.1158/0008-5472.CAN-13-0777
31. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
32. + T cells induced by melanoma vaccines. Cancer Res 2014; 74:1045-55; PMID:24343228; http://dx.doi.org/10.1158/0008-5472.CAN-13-2908
33. Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013; 2:e27010; PMID:24498547; http://dx.doi.org/10.4161/onci.27010
34. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/onci.23510
35. Maio M, Di Giacomo AM, Robert C, Eggermont AMM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol 2013; 25:166-72; PMID:23299197; http://dx.doi.org/10.1097/CCO.0b013e32835dae4f
36. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27; PMID:21631324; http://dx.doi.org/10.1056/NEJMoa1012863
37. Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J ClinOncol 2013; 31:2369-71; PMID:23715576; http://dx.doi.org/10.1200/JCO.2013.49.2157